Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$7.3 million.

  • Mereo BioPharma Group's Free Cash Flow rose 2.79% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.7 million, marking a year-over-year decrease of 8.36%. This contributed to the annual value of -$32.8 million for FY2024, which is 55.38% down from last year.
  • According to the latest figures from Q3 2025, Mereo BioPharma Group's Free Cash Flow is -$7.3 million, which was up 4.47% from -$7.7 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Free Cash Flow peaked at $2.7 million during Q3 2023, and registered a low of -$9.4 million during Q4 2024.
  • Over the past 3 years, Mereo BioPharma Group's median Free Cash Flow value was -$7.8 million (recorded in 2023), while the average stood at -$7.0 million.
  • The largest annual percentage gain for Mereo BioPharma Group's Free Cash Flow in the last 5 years was 13.59% (2024), contrasted with its biggest fall of 382.78% (2024).
  • Over the past 3 years, Mereo BioPharma Group's Free Cash Flow (Quarterly) stood at -$6.8 million in 2023, then slumped by 38.75% to -$9.4 million in 2024, then climbed by 2.79% to -$7.3 million in 2025.
  • Its Free Cash Flow was -$7.3 million in Q3 2025, compared to -$7.7 million in Q2 2025 and -$8.3 million in Q1 2025.